Multi-level Determinants of Starting ART Late: Aim 3

Completed

• Conditions: Human Immunodeficiency Virus (HIV); Acquired Immune Deficiency Syndrome (AIDS)

• Registration Number: NCT01997359
• Lead Sponsor: Columbia University

Brief Summary

The availability of HIV care and treatment programs is increasing in sub-Saharan Africa. However more than half the patients who need HIV treatment are still not receiving antiretroviral therapy (ART). This can lead to early death from AIDS. Additionally, many patients start ART late after the HIV disease is very advanced. This results in high death rates soon after starting ART. The factors that contribute to late ART initiation are still unclear. This study will identify factors that help patients to enroll or prevent them from enrolling into HIV care and starting ART on time. We will examine the characteristics of all patients initiating ART at study sites. We will also look at potential risk factors among patients who initiate ART late (cases) compared to patients who initiate earlier (controls) at 6 HIV care and treatment clinics in Ethiopia. Data will be collected using 2 methods:

1. Face-to-face interviews with participants using questionnaires

2. Obtaining clinical data from the electronic patient-level database

Identifying factors that help patients to start or prevent them from starting ART on time will help to direct interventions, programs and policies to reduce early death.

Detailed Description

Background: Although HIV care and treatment programs are being scaled up in sub-Saharan Africa, more than 50% of the patients in need of ART are not receiving it and there is still significant mortality from AIDS. One of the major challenges is high rates of late ART initiation (i.e., in the advanced stages of HIV disease) which results in high rates of mortality soon after initiation of ART. The individual-level factors that contribute to late ART initiation are still unclear. Objective: As the 3rd part of a 3-phase NIH-sponsored project, this study aims to identify individual-level enablers and barriers to timely enrollment into HIV care and ART initiation.

Methods: We will be recruiting all patients newly initiating ART at the study sites for descriptive analysis (approximately 1,200). As a sub-analysis, we will be utilizing a case-control approach to examine potential individual risk factors (e.g. knowledge and behaviors around HIV care and treatment, experience of stigma, and other perceived barriers and enablers to earlier HIV diagnosis, enrollment into care, and ART initiation) among 360 patients who initiated ART late (CD4 count \<150 cells/µL compared to 360 patients who initiated earlier (CD4≥200) at 6 HIV care and treatment clinics in Ethiopia. For both the descriptive study and case-control study, data will be collected using 2 methods:

1. Face-to-face interviews with participants using structured questionnaires

2. Abstraction of clinical data from the electronic patient-level database to capture patient information at baseline, 6 and 12 months after enrollment in the study

Expected use of results: Identifying individual-level enablers and barriers of timely ART initiation will facilitate implementation of interventions, programs and policies to mitigate the problem of late ART initiation.

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2013-11-08
• Study First Submitted QC: 2013-11-22
• Study First Posted: 2013-11-28
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-15
• Last Update Posted: 2014-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1214

Inclusion Criteria

• Aged 18 years (the age of majority in Ethiopia) or older.

• ART naïve.

• Eligible for ART according to Ethiopia's National ART guideline criteria.

• Have received a prescription for ART during the study period.

• Speak either Oromiffa or Amharic.

• Special inclusion criteria for case-control sub-analysis:

  • Cases: CD4 count <150 cells/µL (regardless of WHO stage)
  • Controls: CD4 ≥200.

Read More

Exclusion Criteria

• Overtly cognitively impaired
• Inability or unwillingness to provide informed consent
• Actively incarcerated

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of Persons Initiating ART Late	12 months

Trial Locations

Locations (6)

Ambo Hospital; 🇪🇹 Ambo, Ethiopia

Bishoftu Hospital; 🇪🇹 Bishoftu, Ethiopia

Fitche Hospital; 🇪🇹 Fitche, Ethiopia

Shashamene Hospital; 🇪🇹 Shashamene, Ethiopia

Goba Hospital; 🇪🇹 Goba, Ethiopia

Nekemte Hospital; 🇪🇹 Nekemte, Ethiopia